All Clinical Trials
Mater conducts clinical trials in a range of therapeutic areas including Cance, Nerouology, Medicine, Orthopaedics Surgery and Acute Care, and Mothers' and Babies Health. Clinical trials are an essential component of helathcare. They provide the evidence to evaluate the safety and efficacy of new treantments and diagnositics, and provide alternative treatment options for patients with unmet needs.
FAME 1 Eye research study - A new treatment for retinopathy in type 1 diabetes
Testing the safety and effectiveness of Fenofibrate in reducing diabetic retinopathy in adults with Type 1 diabetes
FOCUSau: Improving the wellbeing of people with advanced cancer and their family carers
Improving the wellbeing of people with advanced cancer and their family carers: An effectiveness implementation trial of an Australian dyadic digital health intervention (FOCUSau).
frontMIND - A new treatment for newly diagnosed lymphoma
A clinical trial of investigational drug tafasitamab plus lenalidomide in addition to standard therapy for treatment of newly diagnosed high and intermediate risk diffuse large B-cell lymphoma (DLBCL)
FUZION - A potential treatment for Fistulizing, Perianal Crohn’s Disease
FUZION: Efficacy and safety of guselkumab in participants with fistulizing, perianal Crohn’s Disease
GOLSEEK-2 - Golcadomide plus Rituximab for Follicular Lymphoma
A Study to Assess the Efficacy and Safety of Golcadomide and Rituximab in Participants with Newly Diagnosed Advanced Stage Follicular Lymphoma
HyNOVA - Hyperthermic and Normothermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III epithelial OVArian, fallopian tube and primary peritoneal cancer
This study is investigating the safety of administering heated (42 degrees Celsius) versus normal temperature (37 degrees Celsius) chemotherapy during surgery for ovarian cancer patients.
INX-315-01
This study will investigate the use of a new medicine called INX-315 which may be used in the future as a possible treatment for advanced solid tumours.
IOS-1002-201 - administered alone and in combination with a PD-1 monoclonal antibody in advanced solid tumors
A Phase 1a/1b, first-in-human, open-label, non-randomized, multicenter, dose-escalation and cohort expansion study to evaluate the safety, tolerability, efficacy, immunogenicity, pharmacokinetics, and pharmacodynamics of IOS-1002 administered alone and in combination with a PD-1 monoclonal antibody in advanced solid tumors.
iSEARCH - Improving outcomes for women and babies by increasing placental blood flow to reduce fetal distress during labour
JetPlane CPAP (Continuous Positive Air Pressure) Interface & Accessories Product Evaluation Study – CIA-235